Papers
16
Total Citations
460
H-Index
11
About
Peter Albers is a prominent urological oncologist whose research has profoundly shaped the surgical management of prostate cancer and testicular germ cell tumors. Based at a leading European academic center, Albers has pioneered rigorous comparative surgical trials, most notably the landmark LAP-01 trial — the first multicentre, randomized, patient-blinded study directly comparing robotic-assisted and laparoscopic radical prostatectomy, which has already garnered over 150 citations across its primary and follow-up publications. His work critically evaluates not only oncological outcomes but also quality of life and functional recovery, providing surgeons with evidence-based guidance for patient counseling. Equally significant is Albers' leadership of the PRIMETEST trial, a groundbreaking Phase II study investigating primary retroperitoneal lymph node dissection as a chemotherapy- and radiotherapy-sparing strategy in seminoma patients, accumulating over 100 citations since 2022. His contributions extend to robotic cystectomy safety, MRI-based surgical planning, and minimally invasive retroperitoneal lymph node dissection for testicular cancer. Across his portfolio, Albers consistently challenges surgical dogma through prospective, controlled methodology, making him an indispensable voice in modern uro-oncology and a vital reference for researchers and clinicians navigating evolving treatment paradigms.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10